Details of Disease
General Information of Disease (ID: DISSKW1M)
Disease Name | Neuronal ceroid lipofuscinosis 5 | |||||
---|---|---|---|---|---|---|
Synonyms |
ceroid lipofuscinosis, neuronal, 5; Finnish Vlincl; CLN5 disease, adult; CLN5 disease, late infantile (subtype); ceroid lipofuscinosis, neuronal, 5, variable Age at onset; neuronal ceroid lipofuscinosis Finnish variant; CLN5 disease, juvenile; CLN5 disease; neuronal ceroid lipofuscinosis, late infantile, Finnish variant; neuronal ceroid lipofuscinosis type 5; neuronal ceroid lipofuscinosis caused by mutation in CLN5; neuronal ceroid lipofuscinosis 5 variable age of onset; CLN5 neuronal ceroid lipofuscinosis; ceroid lipofuscinosis, neuronal, type 5; CLN5
|
|||||
Definition |
Neuronal ceroid lipofuscinosis 5 (CLN5-NCL) is a rare condition that affects the nervous system. Signs and symptoms of the condition generally develop between ages 4.5 and 7 years, although later onset cases have been reported. Affected people may experience loss of muscle coordination (ataxia), seizures that do not respond to medications, muscle twitches (myoclonus), visual impairment, and cognitive/motor decline. It occurs predominantly in the Finnish population. CLN5-NCL is caused by changes (mutations) in the CLN5 gene and is inherited in an autosomal recessive manner. Treatment options are limited to therapies that can help relieve some of the symptoms.
|
|||||
Disease Hierarchy | ||||||
Disease Identifiers | ||||||
Molecular Interaction Atlas (MIA) of This Disease
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
This Disease Is Related to 1 DTT Molecule(s)
|
||||||||||||||||||||||||||||||
This Disease Is Related to 2 DOT Molecule(s)
|
||||||||||||||||||||||||||||||
References